MedTrace Logo

Sarcoma Study of MORAb-004 Utilization: Research and Clinical Evaluation

NCT01574716 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 209

Last updated 2019-08-21

Study results available
· View outcomes & findings →

Summary

This study is being done to see if MORAb-004 increases the effectiveness of the chemotherapies gemcitabine and docetaxel in people with metastatic Soft Tissue Sarcoma.

Conditions

  • Metastatic Soft Tissue Sarcoma

Interventions

DRUG

MORAb-004

IV, Days 1 and 8 of every cycle until disease progression

DRUG

Gemcitabine

IV, Days 1 and 8 of each cycle until disease progression

DRUG

Docetaxel

IV, Day 8 of every cycle until disease progression

DRUG

Gemcitabine

IV, Days 1 and 8 of each cycle until disease progression

DRUG

Docetaxel

IV, Day 8 of every cycle until disease progression

DRUG

Placebo

Sponsors & Collaborators

  • Morphotek

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-07
Primary Completion
2015-08-11
Completion
2016-08-02

Countries

  • United States
  • Australia
  • Belgium
  • France
  • Italy
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01574716 on ClinicalTrials.gov